NDAORALCAPSULE
Approved
Jul 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
5
Data completeness
6/8 — Strong
VASCEPA (icosapent ethyl) by Inpharmus is low-density lipoprotein triglycerides (vldl-tg) synthesis and/or secretion and enhances tg clearance from circulating vldl particles. Approved for hypertriglyceridemia, cardiovascular diseases. First approved in 2012.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASCEPA (icosapent ethyl) is an oral prescription fish oil capsule approved in 2012 that reduces triglycerides by inhibiting VLDL-TG synthesis and secretion while enhancing triglyceride clearance from circulating particles. The drug works through multiple mechanisms including increased β-oxidation, inhibition of DGAT, decreased hepatic lipogenesis, and increased plasma lipoprotein lipase activity. It is indicated for patients with elevated triglycerides and is positioned as a specialized lipid management therapy in the cardiovascular prevention landscape.
$0.8BPart D
7.1 years to LOEMechanism of Action
low-density lipoprotein triglycerides (VLDL-TG) synthesis and/or secretion and enhances TG clearance from circulating VLDL particles. Potential mechanisms of action include increased β-oxidation; inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase (DGAT); decreased lipogenesis in the liver;…
Indications (2)
Worked on VASCEPA at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.